These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28648417)

  • 1. Effect of heart failure reversal treatment as add-on therapy in patients with chronic heart failure: A randomized, open-label study.
    Sane R; Aklujkar A; Patil A; Mandole R
    Indian Heart J; 2017; 69(3):299-304. PubMed ID: 28648417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of heart failure reversal treatment in patients with low ejection fraction.
    Rohit S; Rahul M
    J Ayurveda Integr Med; 2018; 9(4):285-289. PubMed ID: 30287144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.
    Pfisterer M; Buser P; Rickli H; Gutmann M; Erne P; Rickenbacher P; Vuillomenet A; Jeker U; Dubach P; Beer H; Yoon SI; Suter T; Osterhues HH; Schieber MM; Hilti P; Schindler R; Brunner-La Rocca HP;
    JAMA; 2009 Jan; 301(4):383-92. PubMed ID: 19176440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy.
    Schmidt S; Hürlimann D; Starck CT; Hindricks G; Lüscher TF; Ruschitzka F; Steffel J
    Eur Heart J; 2014 Apr; 35(16):1051-60. PubMed ID: 24371079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation.
    Kalman J; Buchholz C; Steinmetz M; Courtney M; Gass A; Lansman S; Kukin ML
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1212-7. PubMed ID: 8719469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure.
    Kum LC; Yip GW; Lee PW; Lam YY; Wu EB; Chan AK; Fung JW; Chan JY; Zhang Q; Kong SL; Yu CM
    Int J Cardiol; 2008 Mar; 125(1):16-21. PubMed ID: 17433840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.
    Cice G; Di Benedetto A; D'Isa S; D'Andrea A; Marcelli D; Gatti E; Calabrò R
    J Am Coll Cardiol; 2010 Nov; 56(21):1701-8. PubMed ID: 21070920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
    Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.
    Mayer B; Holmer SR; Hengstenberg C; Lieb W; Pfeifer M; Schunkert H
    Int J Cardiol; 2005 Aug; 103(2):182-6. PubMed ID: 16080978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.
    Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE
    Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
    Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
    Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of the efficacy of bisoprolol administration by cardiopulmonary exercise testing in patients with heart failure].
    Terzi S; Dayi SU; Akbulut T; Dağ O; Köse H; Satiroğlu O; Sayar N; Bilsel T; Aksoy S; Yeşilçimen K
    Anadolu Kardiyol Derg; 2003 Dec; 3(4):313-8. PubMed ID: 14675880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
    Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
    Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF.
    Voors AA; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Ter Maaten JM; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Zwinderman AH; Metra M
    Eur J Heart Fail; 2016 Jun; 18(6):716-26. PubMed ID: 27126231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atenolol as add-on therapy to fosinopril in heart failure.
    Pacher R; Hülsmann M; Berger R; Koller-Strametz J; Kos T; Frey B; Dukat A; Stanek B
    Wien Klin Wochenschr; 1997 Apr; 109(7):232-8. PubMed ID: 9141231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of the cardiopulmonary exercise test in patients with heart failure who have been treated with beta-blockers.
    Dufay-Bougon C; Belin A; Dahdouh ZS; Barthelemy S; Mabire JP; Sabatier R; Milliez P; Grollier G
    Turk Kardiyol Dern Ars; 2013 Mar; 41(2):105-12. PubMed ID: 23666296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial.
    Funck-Brentano C; van Veldhuisen DJ; van de Ven LL; Follath F; Goulder M; Willenheimer R;
    Eur J Heart Fail; 2011 Jul; 13(7):765-72. PubMed ID: 21551161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.